A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk

ConditionOverdose
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age13+
SponsorBoston Medical Center

About this trial

Adolescent (ages 10-19) overdose deaths are the third leading cause of pediatric death and continue to rise in the United States. Healthcare providers have regular and trusted relationships with youth and have experience in providing public health injury prevention counseling. Youth have different motivations for using drugs, and many who experience fatal overdose do not have a history of opioid use. Primary care pediatric providers regularly provide developmentally appropriate injury prevention counseling for leading causes of pediatric fatal and nonfatal injury such as drowning prevention and firearms safety. However, there are no recommended, evidence-based overdose prevention interventions for youth, including in health care settings, even though research supports pediatricians and youth-serving clinicians providing harm reduction strategies such as naloxone distribution and overdose education. Among adults, overdose prevention education reduces overdose, is cost-effective, and can be learned by laypersons. Content commonly includes awareness of fentanyl in the drug supply, risk reduction (e.g., not using alone, risks of polysubstance use), and how to recognize and respond to an overdose, including the use of naloxone.

This study is a pilot two-arm cluster randomized controlled trial (RCT) of a brief overdose prevention education intervention that will be developed in collaboration with the Community Advisory Board (CAB). The primary outcome of this study is to assess the feasibility and acceptability of the brief youth overdose prevention intervention as measured by provider feasibility and acceptability as well as youth acceptability.

Eligibility criteria

Qualifiers

Physicians and advance practice providers within Pediatric Primary Care and Family Medicine at Boston Medical Center (BMC)

≥ 2 clinic sessions per/week

Disqualifiers

None

Ages 13-26

Scheduled for a comprehensive physical exam with a provider who is participating in the trial

English speaking

Trial design

Treatments tested in this trial

  • Brief youth overdose prevention education
  • Information about Naloxone
  • Usual standard of care

Treatment groups

24 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Boston Medical Center

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator